Literature DB >> 2129507

Fusidic acid, an immunosuppressive drug with functions similar to cyclosporin A.

K Bendtzen1, M Diamant, V Faber.   

Abstract

Fusidic acid, a tetracyclic triterpenoic acid, is used for local and systemic treatment of bacterial infections. Its in vitro effects on the human immune response were tested. Activated blood mononuclear cells released lower levels of interleukin (IL) 1 in the presence of nontoxic and clinically attainable levels of fuscidic acid (15 to 50 micrograms/mL). In contrast, the drug failed to affect the production of two other monocyte-derived cytokines, tumor necrosis factor (TNF)-alpha and IL 6. The production of the T-cell-derived cytokines, IL 2 and interferon-gamma (IFN-gamma), were also suppressed (IC50: 5 to 15 micrograms/mL). The early costimulatory effects of IL 1 and IL 6 on mouse thymocytes and human T cells were suppressed by similar levels of the drug, as was the hybridoma growth-promoting function of IL 6. T-cell proliferation induced by phytohemagglutinin or allogeneic cells was reversibly inhibited (IC50: 15 micrograms/mL). These functions of fusidic acid were strikingly similar to those of cyclosporin A. Because of the low toxicity of the former, it may have a role as a clinically useful suppressor of immunoinflammatory processes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2129507     DOI: 10.1016/1043-4666(90)90051-t

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  9 in total

1.  Lack of effect of intermittently administered sodium fusidate in patients with newly diagnosed type 1 diabetes mellitus: the FUSIDM trial.

Authors:  I Conget; E Aguilera; S Pellitero; S Näf; K Bendtzen; R Casamitjana; R Gomis; F Nicoletti
Journal:  Diabetologia       Date:  2005-07-02       Impact factor: 10.122

Review 2.  Immunomodulating effects of antibiotics: literature review.

Authors:  B Van Vlem; R Vanholder; P De Paepe; D Vogelaers; S Ringoir
Journal:  Infection       Date:  1996 Jul-Aug       Impact factor: 3.553

3.  Improved survival and antagonistic effect of sodium fusidate on tumor necrosis factor alpha in a neonatal mouse model of endotoxin shock.

Authors:  F Genovese; G Mancuso; M Cuzzola; V Cusumano; F Nicoletti; K Bendtzen; G Teti
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

4.  Effects of sodium fusidate in animal models of insulin-dependent diabetes mellitus and septic shock.

Authors:  F Nicoletti; P Zaccone; R Di Marco; G Magro; S Grasso; S Morrone; A Santoni; G Tempera; P L Meroni; K Bendtzen
Journal:  Immunology       Date:  1995-08       Impact factor: 7.397

5.  Clinical trial of fusidic acid for lepromatous leprosy.

Authors:  S G Franzblau; G P Chan; B G Garcia-Ignacio; V E Chavez; J B Livelo; C L Jimenez; M L Parrilla; R F Calvo; D L Williams; T P Gillis
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

6.  Reduction of spontaneous autoimmune diabetes in diabetes-prone BB rats with the novel immunosuppressant fusidic acid. Effect on T-cell proliferation and production of interferon-gamma.

Authors:  F Nicoletti; R Di Marco; S Morrone; P Zaccone; D Lembo; S Grasso; A Santoni; P L Meroni; K Bendtzen
Journal:  Immunology       Date:  1994-02       Impact factor: 7.397

7.  Antibiotic activity in serum following single and repeated oral administration of sodium fusidate in volunteers.

Authors:  P Munkholm; H Hey; S N Rasmussen; P B Johansen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Oct-Dec       Impact factor: 2.441

8.  Prevention of cyclophosphamide-induced diabetes in the NOD/WEHI mouse with deoxyspergualin.

Authors:  F Nicoletti; M O Borghi; P L Meroni; W Barcellini; C Fain; R Di Marco; R Menta; H U Schorlemmer; G Bruno; G Magro
Journal:  Clin Exp Immunol       Date:  1993-02       Impact factor: 4.330

9.  Placebo controlled trial of fusidic acid gel and oxytetracycline for recurrent blepharitis and rosacea.

Authors:  D V Seal; P Wright; L Ficker; K Hagan; M Troski; P Menday
Journal:  Br J Ophthalmol       Date:  1995-01       Impact factor: 4.638

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.